Real-Time Tissue Change Monitoring on the Sonablate® 500 during High Intensity Focused Ultrasound (HIFU) Treatment of Prostate Cancer

Author(s):  
Wo-Hsing Chen ◽  
Narendra T. Sanghvi ◽  
Roy Carlson ◽  
Toyoaki Uchida ◽  
Yoichiro Matsumoto ◽  
...  
2013 ◽  
Vol 63 (2) ◽  
pp. 395-398 ◽  
Author(s):  
Alessandro Napoli ◽  
Michele Anzidei ◽  
Cosimo De Nunzio ◽  
Gaia Cartocci ◽  
Valeria Panebianco ◽  
...  

2008 ◽  
Vol 75 (4) ◽  
pp. 199-206
Author(s):  
G. Vespasiani ◽  
A.D. Asimakopoulos ◽  
E. Finazzi Agrò ◽  
G. Virgili

Background. The potential applications of the high-intensity focused ultrasound (HIFU) as a minimally invasive therapy of the localized prostate cancer explain the growing interest of the urologic community towards this technique. HIFU has been assessed for its role in the treatment of localized prostate cancer in patients who otherwise would not have benefited from surgery, and in local recurrences after radiation failure. Methods. Relevant information on HIFU treatment was identified through a literature search of published studies. Results. High biochemical efficacy, excellent tumor local control and favorable mid- and long-term oncological data with a low morbidity rate have been shown in many series of patients. Conclusions. Although HIFU is a recent and emerging technology, it has been well studied and developed to a point that HIFU will undoubtedly be an effective alternative to radiation therapy.


2017 ◽  
Vol 2017 ◽  
pp. 1-3
Author(s):  
Leon Telis ◽  
Seyed Behzad Jazayeri ◽  
David B. Samadi

Background. Prostate cancer is the most common cancer diagnosed in men. As new focal therapies become more popular in treatment of prostate cancer, failure cases requiring salvage therapy with either surgical or other techniques are being reported. Objective. To report the options in treatment of prostate cancer after recurrence or failure of the primary treatment modality. Methods. We report a salvage robotic assisted laparoscopic radical prostatectomy (RALP) for prostate cancer recurrence following high intensity focused ultrasound treatment (HIFU) in the United States. Results. A 67-year-old man who underwent HIFU treatment for prostate adenocarcinoma 2 years prior was presented with a rising prostate specific antigen of 6.1 ng/mL to our clinic. A biopsy proven recurrent disease in the area of previous treatment documented the failure of treatment. The patient elected to undergo a salvage RALP. The operation time was 159 minutes. The patient was discharged from the hospital on postoperative day 1 with no complications. The catheter was removed on post-op day 10. The patient reserved sexual function and urinary continence. The PSA levels on 6 months’ follow-up are undetectable. Conclusions. Salvage RALP is an effective and safe treatment choice for recurrent prostate adenocarcinoma following failed HIFU treatment if operated by an experienced surgeon.


Urology ◽  
2020 ◽  
Author(s):  
Renato Vasconcelos Souza de Almeida ◽  
José Ricardo Cruz Silvino ◽  
Jamile Rosario Kalil ◽  
Vitor Lazarini dos Santos ◽  
Vinicius Meneguette Gomes de Souza ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document